Anika Therapeutics (ANIK) Return on Capital Employed (2011 - 2026)
Anika Therapeutics (ANIK) reported Return on Capital Employed of 7.48% for Q1 2026, down 363.0% year-over-year from 2.84% in Q1 2025, and down 13.66% quarter-over-quarter from 6.58% in Q4 2025.
Anika Therapeutics (ANIK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 16 years of Return on Capital Employed data on file, last reported at 7.48% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 7.48%, down 363.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 7.48% (down 363.0% YoY), and the FY2025 annual result was 6.33%, down 394.0% from the prior year.
- Return on Capital Employed fell to 7.48% in Q1 2026 per ANIK's latest filing, from 6.58% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 9.17% in Q3 2024 and troughed at 7.48% in Q1 2026.
- A 5-year average of 1.8% and a median of 2.48% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 1165 bps in 2024, then plunged 1648 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 1.15% in 2022, then plunged by 73 bps to 0.31% in 2023, then tumbled by 937 bps to 2.63% in 2024, then tumbled by 150 bps to 6.58% in 2025, then declined by 14 bps to 7.48% in 2026.
- Business Quant data shows ANIK's Return on Capital Employed at 7.48% in Q1 2026, 6.58% in Q4 2025, and 7.32% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -7.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.48% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -7.32% |
| Jun 30, 2025 | -5.34% |
| Mar 31, 2025 | -3.85% |
| Dec 31, 2024 | -2.63% |
| Sep 30, 2024 | 9.17% |
| Jun 30, 2024 | 5.36% |
| Mar 31, 2024 | 4.56% |
| Dec 31, 2023 | 0.31% |
| Sep 30, 2023 | -2.48% |
| Jun 30, 2023 | -1.80% |
| Mar 31, 2023 | -1.69% |
| Dec 31, 2022 | 1.15% |
| Sep 30, 2022 | -6.73% |
| Jun 30, 2022 | -4.63% |
| Mar 31, 2022 | -0.69% |
| Dec 31, 2021 | 0.82% |
| Sep 30, 2021 | -1.89% |
| Jun 30, 2021 | -4.81% |